25 results about "Guanosine" patented technology

This application discloses a cyclic GMP-AMP synthase mutant. Compared to the wild-type cyclic GMP-AMP synthase shown in SEQ ID NO.1, the amino acid sequence of the cyclic GMP-AMP synthase mutant has any one of the following mutations: L377M or H437T / S434T. Specifically, the amino acid sequence of the L377M mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.4, and the amino acid sequence of the H437T / S434T mutated cyclic GMP-AMP synthase mutant is shown in SEQ ID NO.9. The cGAS mutant of this application exhibits four times the activity of the wild-type. The preparation method uses readily available and economical raw materials, is simple to operate, environmentally friendly, and pollution-free, with high synthesis efficiency, making it suitable for industrial development.

A method for increasing or improving nitric oxide signals or levels, the method comprising: administering a composition to a subject, the composition comprising: arginine or a pharmaceutically acceptable salt, ester, or derivative thereof; and tetrahydrocurcumin and / or β-aminoisobutyric acid or a pharmaceutically acceptable salt or ester thereof. The method and the composition can be used to increase, improve, or enhance nitric oxide signals or levels, inhibit nitric oxide decomposition, and increase or enhance nitrous acid and / or cyclic guanosine monophosphate levels, and can improve fatigue resistance or enhance muscle strength, maintain or improve cardiovascular health, maintain or improve vascular function and structure, inhibit or mitigate endothelial cell damage, or mitigate insufficient blood flow.

The present application relates to the cosmetic technical field, specifically to a composition containing guanosine component and capable of promoting scalp epidermal cell regeneration and a preparation method, which comprises the following raw material components in percentage by weight: 0.5-20% of surfactant AES, 0.5-10% of biota extract, 0.5-12% of pueraria extract, 0.5-12% of ginger extract, 0.5-10% of ginsenoside extract, 0.5-10% of hydrolyzed corn starch, 0.2-2% of tetraphosphoric acid di-guanosine (GP4G), 1-10% of base liquid, 1-5% of humectant, 0.1-2% of thickening agent, 0.01-1.0% of preservative, and the rest is deionized water. The formula has no irritation, is mild, can significantly increase hair growth and hair volume, increase hair follicle hair retention, inhibit hair loss, promote the re-development of hair follicles, has very significant dandruff and itching relieving functions, and has a simple operation process, and is suitable for industrial manufacturing.

This invention discloses *Pediococcus lactis* TC-4, which simultaneously degrades nucleosides, purines, and uric acid, and its applications. *Pediococcus lactis* ( Pediococcus acidilactici This invention relates to *Pediococcus lactis* TC-4, with accession number GDMCC No: 67936. *Pediococcus lactis* TC-4 of this invention can efficiently degrade three nucleosides (guanosine, adenosine, and inosine), three purines (guanine, xanthine, and hypoxanthine), and uric acid in vitro. *Pediococcus lactis* TC-4 of this invention can effectively reduce serum uric acid levels in broiler chickens, alleviating and treating hyperuricemia. Compared with traditional chemical drugs for treating hyperuricemia and / or gout, this invention has no toxic side effects on the ecological environment, no residue risk, and is green and safe. This invention has been confirmed at multiple levels, including genetic and animal studies, to have no potential harm to humans, demonstrating its advantages of safety and high efficiency.

This invention relates to the field of probiotics technology, specifically to a Bifidobacterium adolescentis BN18 and its postbiotics for lowering uric acid and improving gout symptoms, and their applications. The Bifidobacterium adolescentis BN18 can promote the degradation of inosine and guanosine, thereby reducing uric acid levels in the blood. The postbiotics for Bifidobacterium adolescentis BN18 are made from carefully selected raw materials such as carrots, winter melon, blueberries, apples, lemons, and fructooligosaccharides as the core components of the composition. Through deep fermentation with BN18, the resulting postbiotics not only reduce the activity of xanthine oxidase and lower uric acid levels in the blood, thus promoting uric acid reduction, but also significantly enhance their antioxidant properties, reducing inflammatory responses, lowering inflammation levels, alleviating joint pain, and improving gout symptoms.

This invention provides a highly selective and sensitive fluorescent probe for mercury ions, its preparation method, and its applications, belonging to the fields of chemical sensing materials and environmental monitoring technology. This invention connects 4-(1,2,2-triphenylvinyl)phenol, which exhibits aggregation-induced emission, and a guanosine derivative with multiple coordination sites, via a flexible chain to obtain a fluorescent probe with the structure shown in Formula I. This fluorescent probe not only overcomes the problems of large differences in solubility and reactivity between 4-(1,2,2-triphenylvinyl)phenol and guanosine derivatives, making coupling difficult, but also possesses high sensitivity and selectivity; its detection limit reaches 12.24 nM, effectively detecting trace mercury pollution in samples. It can also accurately identify mercury ions in water samples containing multiple high concentrations of metal ions, demonstrating high accuracy in real water samples. It is suitable for the accurate determination of mercury ions in complex environmental water samples and has good practical application value in the field of environmental monitoring. Formula I

This invention belongs to the field of biotechnology and relates to a strain of *Weizmannii coagulans* NJ01 for the biodegradation of inosine and guanosine, which can produce enzymes that catalyze the degradation of inosine and guanosine. This invention also relates to a preparation of *Weizmannii coagulans* NJ01 for degrading inosine and guanosine, containing bacterial cells and / or crude enzymes of the aforementioned *Weizmannii coagulans* NJ01 strain. Research results show that the *Weizmannii coagulans* NJ01 strain and its produced enzymes provided by this invention are safe for human use and can efficiently biodegrade inosine and guanosine, demonstrating significant value and application prospects in the removal of inosine and guanosine for the prevention and treatment of hyperuricemia, gout, and related complications in humans.

The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various mitochondrial diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′,5′-monophosphate (cGMP) or both, or an upregulation of the NO-sGC-cGMP pathway is desirable. Compounds useful in the methods of the invention are those of Formula I or pharmaceutically acceptable salts thereof.

The application provides a metal ion independent supramolecular hydrogel and a preparation method and application thereof, and belongs to the field of biomedical materials. The guanosine supramolecular hydrogel is prepared from 8-hydroxyguanosine or 8-aminoguanosine, boric acid and water in a weak alkali environment with a pH value of 7.5-8, and the ratio of 8-hydroxyguanosine or 8-aminoguanosine, boric acid and water is (0.025-0.1) mmol:(0.0125-0.1) mmol:1000 muL. The supramolecular hydrogel prepared from 8-hydroxyguanosine (C8) instead of guanosine derivatives can be gelled without metal ions, and also has good mechanical properties, so that the supramolecular hydrogel has a wide application prospect.

The application discloses application of guanosine diphosphate mannose (GDP-M) or a key enzyme GMPPA thereof in the upstream in preparation of a product for predicting a homologous recombination repair deficiency (HRD) level of triple-negative breast cancer. The application also discloses a method for treating triple-negative breast cancer by supplementing GDP-M and / or a GMPPA inhibitor to increase sensitivity to a DNA damage drug.

The present application relates to a novel glutamine-hydrolyzing GMP synthase variant and a method for producing 5'-guanosine monophosphate by using same. A microorganism into which the glutamine-hydrolyzing GMP synthase variant of the present application is introduced is cultured to enable high-yield GMP production.

The present disclosure provides a compound of formula (I): JPEG2026501225000412.jpg44166 [Rings A and R in the formula 1 , R 2 , R 3 , R 4 and m are described herein] or pharmaceutically acceptable salts thereof, methods of preparation, methods of treatment, and pharmaceutical compositions containing same. The present disclosure further relates to the use of compounds of formula (I) and pharmaceutically acceptable salts thereof in the treatment of cGAS-related diseases and disorders.

Disclosed herein are telomere-targeting phosphatidyl-thio conjugates comprising the nucleoside analogs 6-thio-2'-deoxyguanosine and 6-thioguanosine, which target telomeres in cancer cells, and pharmaceutical compositions thereof, and therapeutic methods for administering a therapeutically effective amount of the telomere-targeting phosphatidyl-thio conjugate compounds to treat cancers such as colorectal cancer, non-small cell lung cancer, and hepatocellular carcinoma.

The present application belongs to the technical field of biological medicine, and particularly relates to a multifunctional peptide and application thereof in anti-inflammation, antibiosis, mucosa repair and intestinal secretion promotion. Specifically, the present application designs a polypeptide and analogs with both guanylate cyclase C receptor (GUCY2C) agonist activity and anti-inflammatory, antibacterial and mucosa repair functions. The polypeptide can not only bind with GUCY2C, stimulate the production of intracellular cyclic guanosine monophosphate (cGMP), promote intestinal fluid secretion, but also inhibit the release of pro-inflammatory factors, reduce inflammatory response, promote the repair of intestinal mucosa damaged, and inhibit the growth of opportunistic pathogenic bacteria, accelerate the recovery of intestinal homeostasis after intestinal preparation. While effectively promoting intestinal cleaning, the polypeptide does not cause intestinal inflammation and mucosa damage, has no hemolytic toxicity and cytotoxicity, is high in safety, and has a good clinical application prospect.

A method for preparing fucose and intermediates thereof and applications thereof. In the method for synthesizing GDP-fucose, GDP-fucose is generated by catalytic reaction of sucrose synthase, CDP-threose 2-epimerase, GDP-mannose dehydratase and isomerase with guanosine diphosphate and sucrose as substrates. In the method for synthesizing fucosyllactose, fucosyllactose is obtained by catalytic action of Hp13FucT2 enzyme with GDP-fucose and pNP-lactose as initial substrates. In the method for preparing L-fucose by enzyme, L-fucose is generated by catalytic reaction of fucosidase with fucosyllactose as substrate. The E. coli expression system has the characteristics of high expression efficiency, large expression amount, low cost and easy operation, and the expressed fucosidase has the advantages of high purity and high yield.

This invention relates to a strain of *Lactobacillus plantarum* with uric acid-lowering function (…). Lactobacillus plantarum YLW67 and its applications: This strain was isolated from red sour soup, a traditional fermented food from Guizhou, and is deposited at CGMCC, accession number No. 37373. This strain exhibits excellent tolerance to the gastrointestinal environment, with a survival rate exceeding 40% after treatment in simulated gastric fluid at pH 3.0 and simulated intestinal fluid at pH 8.0. In vitro experiments show that it can completely degrade inosine and guanosine within 9 hours. Animal experiments have confirmed that it can effectively reduce serum uric acid levels in hyperuricemia model mice. This invention also provides a probiotic composition containing this strain and its preparation method, including steps such as large-scale culture, cell collection, freeze-drying, and formulation. This strain and composition can be used to prepare uric acid-lowering functional foods, health foods, or dietary supplements, and have promising applications in improving hyperuricemia and related metabolic diseases.

The present invention relates to a ribonucleic acid construct capable of inducing an immune response, comprising a double-stranded ribonucleic acid sequence of 8 to 17 ribonucleotides in length, the 5'end of at least one strand of said sequence comprising at least one triphosphoric acid (triphosphoric acid) and on at least one strand of said sequence a single-stranded protruding end, wherein the single-stranded protruding end comprises at least one guanosine. The invention also relates to the use of said constructs as vaccines or as immunoadjuvants, and to ribonucleic acid constructs for use as medicaments or in methods for the treatment or prevention of diseases, in particular in methods for the treatment or prevention of viral infections or cancer. The invention also relates to a pharmaceutical composition and a kit comprising the ribonucleic acid construct.

This invention provides a biomass phosphorus-nitrogen hybrid flame retardant, its preparation method, and its application, belonging to the field of functional modification and flame retardant technology of polymer materials. The biomass phosphorus-nitrogen hybrid flame retardant has a flower-like structure and excellent flame retardancy. It is synthesized from different metal chloride salts (ferric chloride, copper chloride, zinc chloride, etc.), guanosine phosphate (5'-triguanosine sodium phosphate, 5'-guanosine triphosphate, 5'-guanosine disodium hydrate), and phosphonates (dimethyl hydroxymethylphosphonate, dimethyl methylphosphonate, dimethyl vinylphosphonate) as raw materials using co-precipitation and adsorption methods. The flame-retardant epoxy resin is formed by adding the biomass phosphorus-nitrogen hybrid flame retardant to an epoxy resin matrix and then curing it. This invention features a simple process, controllable conditions, and the resulting flame retardant exhibits high thermal stability and flame retardant properties. It also shows good compatibility with epoxy resin, significantly improving the flame retardant effect of epoxy resin and possessing broad industrial application prospects.

The disclosure provides for the culture media particularly suitable to culture primary ostrich PGCs. The culture media contain specific growth factors and compounds that provide support for the growth and proliferation of ostrich PGCs. In certain embodiments, the culture media contain a basal culture medium and β-mercaptoethanol, cholesterol, FGF1, FGF2, BMP4, and IGF1. In some embodiments, the basal culture medium contains knock-out DMEM, B27 Supplement, MEM-MEAA, L-alanyl-L-glutamine dipeptide, cytidine, guanosine, uridine, adenosine, thymidine, sodium pyruvate, ovalbumin, sodium heparin, calcium chloride, ovotransferrin, and an antibiotic. The disclosure also includes methods and kits for producing such media as well as methods of culturing cells.

The present invention provides immunogenic compositions, kits, and methods suitable for stimulating an immune response to varicella-zoster virus (VZV) in individuals requiring such stimulation. [Solution] An immunogenic composition is provided comprising varicella-zoster virus (VZV) glycoprotein E antigen and a Toll-like receptor 9 (TLR9) agonist, such as an oligonucleotide containing a non-methylated cytidine-phospho-guanosine (CpG) motif.

This invention relates to molecular diagnostic techniques for tuberculosis, specifically to a drug resistance marker based on the level of 7-methylguanosine modification on Mycobacterium tuberculosis RNA and its application. The marker is 7-methylguanosine m-modified guanosine on Mycobacterium tuberculosis RNA. 7 G-modification, m in drug-resistant Mycobacterium tuberculosis RNA 7 The level of G modification is positively correlated with the drug resistance of Mycobacterium tuberculosis. The drug resistance biomarker of this invention enables rapid, accurate, and early drug resistance detection, and the biomarker's drug resistance prediction has the characteristics of wider drug coverage and better versatility, meeting the clinical need for rapid, broad-spectrum, and efficient screening for multidrug resistance in Mycobacterium tuberculosis.

The present application relates to the technical field of nucleotide synthesis, and particularly relates to a 3'-ONH2-deoxyguanosine acid analogue, a preparation method and application thereof, a 7-position nitrogen atom on a base purine ring of the 3'-ONH2-deoxyguanosine acid analogue is substituted by a carbon atom, the change in the structure makes hydrogen bond interaction force between the 3'-ONH2-deoxyguanosine acid analogue and dCTP weaker, the guanosine acid analogue provided by the present application is used to completely replace or partially replace dGTP to reduce the interaction force between GC, effectively reduce the PCR reaction error rate, improve the yield of DNA sequence, and is expected to be applied in gene synthesis, drug preparation and nucleic acid sequence analysis; the preparation method of the 3'-ONH2-deoxyguanosine acid analogue provided by the present application is used for synthesizing 7-deazone modified nucleosides by applying glycosylation reaction, introducing 3-ONH2 modification through twice configuration inversion of 3-position hydroxyl groups on a sugar ring, protecting 3-ONH2 by using acetone, then performing phosphorylation, and finally deprotecting to synthesize the 3'-ONH2-deoxyguanosine acid analogue, the preparation method has mild reaction conditions, is easy to operate, and is beneficial to large-scale production.

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and / or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an uregulation of the NO pathway is desirable. In some embodiments, the compounds are those of Formula I or a pharmaceutically acceptable salt thereof. (I)

This invention discloses two strains of *Lactobacillus reuteri* that are highly efficient at degrading nucleosides and their applications. *Lactobacillus reuteri* ( Limosilactobacillus reuteri The *Lactobacillus reuteri* strains W6-12 and W6-5, with accession numbers GDMCC No. 67938 and GDMCC No. 67937, respectively, exhibit efficient in vitro degradation of adenosine, guanosine, and inosine. In vivo, they significantly reduce serum uric acid levels in HUA broiler chickens induced by high calcium and high protein intake. Their fermented milk significantly reduces serum uric acid levels in SD rats with hyperuricemia induced by potassium hypoxanthine and hypoxanthine. This invention has been confirmed at multiple levels, including genetic and animal studies, to pose no potential harm to humans, demonstrating its safety and high efficiency.

This disclosure provides novel piperidine and guanosine-derived ligands that specifically bind to the desialyl glycoprotein receptor (ASGPR) and nucleotide analogs conjugated thereto, said nucleotide analogs being incorporated into oligonucleotides, including double-stranded oligonucleotides such as siRNA.